Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the insider now owns 28,884,540 shares in the company, valued at $231,076,320. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Ionis Pharmaceuticals, Inc. (IONS) opened at 48.06 on Thursday. The stock’s market cap is $5.96 billion. The firm’s 50-day moving average is $53.14 and its 200 day moving average is $46.85. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $60.01.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The firm had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. During the same period in the prior year, the company posted ($0.47) earnings per share. The firm’s revenue for the quarter was up 170.7% compared to the same quarter last year. On average, analysts anticipate that Ionis Pharmaceuticals, Inc. will post $0.05 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Major Shareholder Acquires $25,000,000.00 in Stock” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/08/10/ionis-pharmaceuticals-inc-purchases-3125000-shares-of-ionis-pharmaceuticals-inc-nasdaqions-stock-updated-updated.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC increased its position in Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after buying an additional 800 shares in the last quarter. Hanseatic Management Services Inc. purchased a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $138,000. Westpac Banking Corp purchased a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $171,000. Cambridge Investment Research Advisors Inc. purchased a new position in Ionis Pharmaceuticals during the second quarter valued at approximately $222,000. Finally, Cheyne Capital Management UK LLP bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth about $249,000. 88.77% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on IONS shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $59.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, April 26th. Piper Jaffray Companies set a $51.00 price target on shares of Ionis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Leerink Swann reaffirmed an “outperform” rating and set a $45.00 price target (down previously from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Finally, Cowen and Company reissued a “market perform” rating on shares of Ionis Pharmaceuticals in a report on Monday, May 22nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $47.05.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.